Fig. 2

Changes in lipid profiles after switching to cabotegravir plus rilpivirine. Changes in HDL-c (A), T-chol/HDL-c (B), and LDL-c (C) during the switch to cabotegravir plus rilpivirine in all participants are shown. The analysis for each antiretroviral therapy regimen prior to switching shows changes in HDL-c (D), T-chol/HDL-c (E), and LDL-c (F) in the TAF-based regimen group, and changes in HDL-c (G), T-chol/HDL-c (H), and LDL-c (I) in the DTG-based regimen group. Baseline, at the start of oral-lead-in; month 0, at the start of injectable cabotegravir plus rilpivirine. HDL-c, high-density lipoprotein-cholesterol; T-chol, total cholesterol; LDL-c, low-density lipoprotein-cholesterol. The p-values in the graphs are calculated by the Wilcoxon signed-rank test comparing the values at baseline and at month 7. TAF, tenofovir alafenamide; DTG, dolutegravir